Incidence of radiation pneumonitis after hepatic intra-arterial radiotherapy with yttrium-90 microspheres assuming uniform lung distribution
- PMID: 18838878
- DOI: 10.1097/COC.0b013e318168ef65
Incidence of radiation pneumonitis after hepatic intra-arterial radiotherapy with yttrium-90 microspheres assuming uniform lung distribution
Abstract
Objective: To assess the incidence of clinical and imaging radiation pneumonitis (RP) in a cohort of patients treated with >30 Gy cumulative lung dose (CLD) using Y90 microspheres.
Materials and methods: Four hundred three patients were treated with Y90 microspheres during a 4-year period. Of these, 58 patients received >30 Gy CLD. Patients were followed for toxicities suggestive of imaging or clinical RP. Toxicities were graded using the Radiation Therapy Oncology Group/European Organisation for Research and Treatment of Cancer Late Radiation Morbidity Scoring Schema. Patients were also followed for survival from time of first treatment.
Results: There were 44 men and 14 women. Forty-three patients had hepatocellular carcinoma (HCC), whereas 15 had liver metastases. Mean and median follow-up were 7.3 and 6.0 months, respectively. Mean lung shunt fraction was slightly greater in the patients with HCC versus metastases (20% vs. 16.7%, P = 0.2308). The lifetime CLD for metastases and HCC groups were not statistically different (54.04 Gy vs. 48.44 Gy, P = 0.4303). Forty-three of 53 patients demonstrated no lung imaging findings suggestive of pneumonitis. Imaging findings in 10 patients included pleural effusions, atelectasis, and ground glass attenuation. There were no cases of clinical or imaging RP. Survival varied depending on stage as well as single and CLD. None of the patient deaths were attributed to respiratory compromise.
Conclusion: RP was not predicted using the currently used Y90 dosimetry models that assume uniform distribution in the lungs. Further investigation and dose escalation studies are required to more precisely define the radiation tolerance of lung parenchyma using this mode of therapy.
Similar articles
-
Radiation dose limits and liver toxicities resulting from multiple yttrium-90 radioembolization treatments for hepatocellular carcinoma.J Vasc Interv Radiol. 2007 Nov;18(11):1375-82. doi: 10.1016/j.jvir.2007.07.016. J Vasc Interv Radiol. 2007. PMID: 18003987 Clinical Trial.
-
Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres.J Nucl Med. 2000 Oct;41(10):1673-81. J Nucl Med. 2000. PMID: 11037997
-
Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes.Gastroenterology. 2010 Jan;138(1):52-64. doi: 10.1053/j.gastro.2009.09.006. Epub 2009 Sep 18. Gastroenterology. 2010. PMID: 19766639 Clinical Trial.
-
Need, feasibility and convenience of dosimetric treatment planning in liver selective internal radiation therapy with (90)Y microspheres: the experience of the National Tumor Institute of Milan.Q J Nucl Med Mol Imaging. 2011 Apr;55(2):168-97. Q J Nucl Med Mol Imaging. 2011. PMID: 21386789 Review.
-
Pathologic response and microdosimetry of (90)Y microspheres in man: review of four explanted whole livers.Int J Radiat Oncol Biol Phys. 2004 Dec 1;60(5):1552-63. doi: 10.1016/j.ijrobp.2004.09.004. Int J Radiat Oncol Biol Phys. 2004. PMID: 15590187 Review.
Cited by
-
Quantitative differences in volumetric calculations for radiation dosimetry in segmental Y90 treatment planning using hybrid angiography-CT compared with anatomic segmentation.Br J Radiol. 2024 Feb 2;97(1154):353-362. doi: 10.1093/bjr/tqad056. Br J Radiol. 2024. PMID: 38308040 Free PMC article.
-
Predictive Factors for Adverse Event Outcomes After Transarterial Radioembolization with Yttrium-90 Resin Microspheres in Europe: Results from the Prospective Observational CIRT Study.Cardiovasc Intervent Radiol. 2023 Jul;46(7):852-867. doi: 10.1007/s00270-023-03391-4. Epub 2023 Mar 13. Cardiovasc Intervent Radiol. 2023. PMID: 36914788 Free PMC article.
-
Voxel-S-Value based 3D treatment planning methods for Y-90 microspheres radioembolization based on Tc-99m-macroaggregated albumin SPECT/CT.Sci Rep. 2023 Mar 10;13(1):4020. doi: 10.1038/s41598-023-30824-4. Sci Rep. 2023. PMID: 36899031 Free PMC article.
-
Radiation pneumonitis following Yttrium-90 radioembolization: A Korean multicenter study.Front Oncol. 2023 Jan 16;13:977160. doi: 10.3389/fonc.2023.977160. eCollection 2023. Front Oncol. 2023. PMID: 36726383 Free PMC article.
-
Non-Invasive Imaging Biomarkers to Predict the Hepatopulmonary Shunt Fraction Before Transarterial Radioembolization in Patients with Hepatocellular Carcinoma.J Hepatocell Carcinoma. 2023 Jan 12;10:27-42. doi: 10.2147/JHC.S391537. eCollection 2023. J Hepatocell Carcinoma. 2023. PMID: 36660411 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical